Literature DB >> 19709755

Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules.

Yi-Chun Lin1, Yi-Chun Huang, Yu-Shan Wang, Rong-Huay Juang, Kuang-Wen Liao, Rea-Min Chu.   

Abstract

Natural killer (NK) cells have been considered to be a group of lymphocytes lacking clonally distributed receptors for antigens typical of T cells and B cells. In some mammalian species, including humans, a subpopulation of CD8(+) peripheral blood lymphocytes (PBLs) exhibits NK activity. This NK subpopulation has not been well characterized in mammals and its characterization is particularly poor in the dog. In this study, we demonstrated that a subset of canine CD8(+) cells derived from PBLs and lymphokine (IL-2)-activated killers (LAKs) of PBLs that was CD3(+), CD4(-), CD21(-), CD5(lo), alpha/betaTCR(+), and gamma/deltaTCR(-) contained substantially higher levels of mRNAs for NK cell-related receptors (NKp30, NKp44, NKG2D, 2B4, and CD16 for PBL, and NKG2D and CD56 for LAK) than the corresponding CD8(-) cells. This subset of CD8(+) lymphocytes derived from LAKs also displayed significantly higher NK cytotoxic activity than the corresponding CD8(-) cells. In contrast, CD8(+) cells derived from nonstimulated PBLs showed very low levels of NK cytotoxic activity. Our results indicate that, in IL-2-stimulated PBLs, canine CD8(+) cells are an important subset associated with NK cytotoxic activity. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19709755     DOI: 10.1016/j.vetimm.2009.07.013

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  8 in total

1.  Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells.

Authors:  Dong-Jun Shin; Ji-Yun Park; Youn-Young Jang; Je-Jung Lee; Youn-Kyung Lee; Myung-Geun Shin; Ji-Youn Jung; William E Carson; Duck Cho; Sang-Ki Kim
Journal:  Vet Immunol Immunopathol       Date:  2013-03-21       Impact factor: 2.046

2.  NCR1+ cells in dogs show phenotypic characteristics of natural killer cells.

Authors:  Christine Grøndahl-Rosado; Tina B Bønsdorff; Hege C Brun-Hansen; Anne K Storset
Journal:  Vet Res Commun       Date:  2014-12-02       Impact factor: 2.459

3.  Isolation and characterization of canine natural killer cells.

Authors:  Helen T Michael; Daisuke Ito; Valarie McCullar; Bin Zhang; Jeffrey S Miller; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2013-06-28       Impact factor: 2.046

4.  Cytotoxicity effect of trastuzumab on canine peripheral blood mononuclear cells.

Authors:  T Oyamada; S Okano
Journal:  Iran J Vet Res       Date:  2020       Impact factor: 1.376

5.  Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.

Authors:  Robert J Canter; Steven K Grossenbacher; Jennifer A Foltz; Ian R Sturgill; Jiwon S Park; Jesus I Luna; Michael S Kent; William T N Culp; Mingyi Chen; Jaime F Modiano; Arta M Monjazeb; Dean A Lee; William J Murphy
Journal:  J Immunother Cancer       Date:  2017-12-19       Impact factor: 13.751

6.  Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats.

Authors:  Noritaka Maeta; Katsutoshi Tamura; Hiroshi Takemitsu; Masahiro Miyabe
Journal:  Open Vet J       Date:  2019-05-13

7.  Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3+CD5dimCD21- Cytotoxic Large Granular Lymphocytes.

Authors:  Soo-Hyeon Lee; Dong-Jun Shin; Yoseop Kim; Cheol-Jung Kim; Je-Jung Lee; Mee Sun Yoon; Tung Nguyen Thanh Uong; Dohyeon Yu; Ji-Youn Jung; Duck Cho; Bock-Gie Jung; Sang-Ki Kim; Guk-Hyun Suh
Journal:  Front Immunol       Date:  2018-04-27       Impact factor: 7.561

Review 8.  Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.

Authors:  Alicia A Gingrich; Jaime F Modiano; Robert J Canter
Journal:  J Clin Med       Date:  2019-10-27       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.